21 January 2020 - Genprex today announced that the U.S FDA has granted fast track Designation for Genprex’s Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib (Tagrisso) for the treatment of non-small cell lung cancer patients with EFGR mutations that progressed after treatment with osimertinib alone.
Oncoprex is comprised of the TUSC2 (Tumor Suppressor Candidate 2) gene complexed with a lipid nanoparticle. TUSC2 is the active agent in Oncoprex.